Nasal spray shows promise for tough asthma in early trial
NCT ID NCT05985694
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested an experimental nasal spray called AD17002 in 40 adults with poorly controlled moderate-to-severe eosinophilic asthma. Participants self-administered the spray twice a week for six weeks. The goal was to see if it could improve lung function and reduce the need for rescue inhalers, while also checking safety and ease of use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AD17002 (a nasal spray immunomodulator)
What this could lead to
If it works, this could point toward a new way to control moderate-to-severe eosinophilic asthma without relying solely on standard inhalers.
What could go wrong
This is an early-phase trial with only 40 people, so results may not apply widely. The treatment may not improve lung function or symptoms, and side effects from the nasal spray are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Taipei Medical University Hospital
Taipei, Taiwan, Taiwan